News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 25, 2014, 07:47 ET

Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Mar 11, 2014, 06:00 ET

Sorrento Therapeutics Appoints Mark Durand to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Mar 06, 2014, 06:00 ET

Sorrento Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...

Mar 06, 2014, 05:50 ET

Sorrento Therapeutics Announces Three Presentations and a Satellite Symposium on Cynviloq™ at the 31st Annual Miami Breast Cancer Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...

Mar 03, 2014, 06:00 ET

Sorrento Therapeutics hires Mike Royal as Senior Vice President of Clinical Development

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...

Feb 11, 2014, 08:00 ET

Sorrento Therapeutics Announces Two Presentations on Cynviloq™ at the Beaujon International Conference on "Cutting Edge in Liver and Pancreatic Tumors"

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Feb 10, 2014, 16:00 ET

Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq™ to Include Australia, Canada and Mexico

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Feb 06, 2014, 08:00 ET

Sorrento Therapeutics to Present at 16th Annual BIO CEO & Investor Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Feb 03, 2014, 06:00 ET

Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated...

Jan 10, 2014, 12:50 ET

Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com) announced today that Dr. Henry Ji, President and Chief Executive...

Jan 09, 2014, 09:00 ET

Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...

Jan 08, 2014, 09:00 ET

Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com), a late-stage clinical oncology company developing new...

Dec 19, 2013, 19:10 ET

Sorrento Therapeutics Completes Acquisition of Concortis Biosystems

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has completed its acquisition of Concortis Biosystems, Corp.,...

Nov 14, 2013, 07:00 ET

Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today the entry into a definitive agreement to acquire San Diego-based Concortis...

Nov 12, 2013, 08:00 ET

Sorrento Therapeutics Adopts Stockholder Rights Plan

Sorrento Therapeutics,  Inc. (NASDAQ: SRNE) announced that its Board of Directors adopted a stockholder rights plan (the "Rights Plan" or...

Nov 05, 2013, 08:00 ET

Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an antibody and vaccine development...

Oct 30, 2013, 14:07 ET

Sorrento Therapeutics Announces Closing of Public Offering of Common Stock

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) today announced the closing of its previously announced underwritten public offering.  The...

Oct 25, 2013, 16:10 ET

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the  full exercise of the over-allotment option granted to the underwriters to...

Oct 24, 2013, 20:29 ET

Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an...

Oct 10, 2013, 19:15 ET

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has acquired Sherrington Pharmaceuticals, Inc. (Sherrington), a...